Начало・Списък с акции・Protagonist Therapeutics Inc

Protagonist Therapeutics Inc

Затворен

СекторЗдравеопазване

135.94 2.91

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

132.13

Максимум

137.77

Ключови измерители
By Trading Economics
Приходи	-82M 3.8M
Продажби	49M 56M
P/E Средно за сектора	131.197 64.641
EPS	0.05
Марж на печалбата	6.711
Служители	131
EBITDA	46M 2.7M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	-0.88% downside

Дивиденти
By Acuity
Следващи печалби	11.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	2.3B 8.7B
Предишно отваряне	133.03
Предишно затваряне	135.94

Настроения в новините

By Acuity

42%

58%

133 / 340 Класиране в Healthcare

Protagonist Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 19:36 ч. UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

31.07.2026 г., 19:36 ч. UTC

Correlated Moves

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

30.07.2026 г., 21:02 ч. UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

29.07.2026 г., 19:43 ч. UTC

Macro Event

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

28.07.2026 г., 21:01 ч. UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.

27.07.2026 г., 20:02 ч. UTC

Social Media

Protagonist Therapeutics shares are lower despite Jefferies raising its price target to $171 and Cowen increasing its peak royalty revenue forecast to $1.4 billion.

22.07.2026 г., 19:42 ч. UTC

News

Protagonist Therapeutics Inc is trading lower today, continuing a decline since Tuesday amid rising crude oil prices and market tensions related to Iran.

21.07.2026 г., 19:06 ч. UTC

Protagonist Therapeutics Inc shares are higher today, continuing an upward trend since Monday's close, supported by gains in the semiconductor sector.

20.07.2026 г., 19:41 ч. UTC

News

Social Media

Protagonist Therapeutics shares are lower as analysts raise price targets and revenue forecasts ahead of Q2 earnings, despite a noted 0% probability of success for PN-881.

Сравнение с други в отрасъла

Ценова промяна

Protagonist Therapeutics Inc Прогноза

Ценова цел

By TipRanks

-0.88% надолу

12-месечна прогноза

Среден 131.11 USD -0.88%

Висок 165 USD

Нисък 110 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Protagonist Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Protagonist Therapeutics Inc през последните 3 месеца.

Настроение

By Acuity

133 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.